Download PDF
TumorDiagnostik & Therapie 2023; 44(08): 540-544
DOI: 10.1055/a-2073-0206
Übersicht
Schwerpunkt

Perioperative Konzepte für resektable Adenokarzinome des Magens und des gastroösophagealen Übergangs

Standard of Care und zukünftige Entwicklungen
Alexander Stein
,
Benjamin Thiele
,
Mascha Binder
› Further Information
Also available at
    Permissions and Reprints

Die Operation stellt den einzigen kurativen Ansatz für resektable Adenokarzinome des Magens und des gastroösophagealen Übergangs dar. Selbst nach Resektion bleibt die Prognose aufgrund hoher Rückfallraten jedoch schlecht. Zur Verringerung von Rückfällen und damit zur Verbesserung des Überlebens wurden neoadjuvante und perioperative Systemtherapieansätze entwickelt. Die optimale Behandlung der nicht metastasierten Erkrankung bleibt allerdings weiterhin Gegenstand aktueller Untersuchungen.

Schlüsselwörter

Adenokarzinom des gastroösophagealen Überganges - Adenokarzinom des Magens - Magenkarzinom - lokalisiert - neoadjuvante Therapie - adjuvante Therapie


Publication History

Article published online:
26 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Santoro E. The history of gastric cancer: legends and chronicles. Gastric Cancer 2005; 8 (02) 71-74 DOI: 10.1007/s10120-005-0325-8. (PMID: 15864712)
    CrossrefPubMedGoogle Scholar
  • 2 Robinson JO. The history of gastric surgery. Postgrad Med J 1960; 36 (422) 706-713 DOI: 10.1136/pgmj.36.422.706. (PMID: 13742310)
    CrossrefPubMedGoogle Scholar
  • 3 DeVita Jr VT, Chu E. A History of Cancer Chemotherapy. Cancer Research 2008; 68 (21) 8643-8653 DOI: 10.1158/0008-5472.CAN-07-6611. (PMID: 18974103)
    CrossrefPubMedGoogle Scholar
  • 4 Macdonald JS, Smalley SR, Benedetti J. et al. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. New England Journal of Medicine 2001; 345 (10) 725-730 DOI: 10.1056/NEJMoa010187. (PMID: 11547741)
    CrossrefPubMedGoogle Scholar
  • 5 Fuchs CS, Niedzwiecki D, Mamon HJ. et al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). JCO 2017; DOI: 10.1200/JCO.2017.74.2130.
    CrossrefPubMedGoogle Scholar
  • 6 Park SH, Sohn TS, Lee J. et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. JCO 2015; 33 (28) 3130-3136 DOI: 10.1200/JCO.2014.58.3930.
    CrossrefPubMedGoogle Scholar
  • 7 Park SH, Lim DH, Sohn TS. et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021; 32 (03) 368-374
    CrossrefPubMedGoogle Scholar
  • 8 Cats A, Jansen EPM, Grieken NCT etl. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. The Lancet Oncology 2018; 19 (05) 616-628 DOI: 10.1016/S1470-2045(18)30132-3. (PMID: 29650363)
    CrossrefPubMedGoogle Scholar
  • 9 Cunningham D, Allum WH, Stenning SP. et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine 2006; 355 (01) 11-20 DOI: 10.1056/NEJMoa055531. (PMID: 16822992)
    CrossrefPubMedGoogle Scholar
  • 10 Ychou M, Boige V, Pignon JP. et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. JCO 2011; 29 (13) 1715-1721 DOI: 10.1200/JCO.2010.33.0597.
    CrossrefPubMedGoogle Scholar
  • 11 Schuhmacher C, Gretschel S, Lordick F. et al. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. JCO 2010; 28 (35) 5210-8 DOI: 10.1200/JCO.2009.26.6114.
    CrossrefPubMedGoogle Scholar
  • 12 Al-Batran SE, Homann N, Schmalenberg H. et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. JCO 2017; 35 (Suppl. 15) 4004-4004 DOI: 10.1200/jco.2017.35.15_suppl.4004. (PMID: 30982686)
    CrossrefPubMedGoogle Scholar
  • 13 Shapiro J, Lanschot JJB van, Hulshof MCCM. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. The Lancet Oncology 2015; 16 (09) 1090-1098 DOI: 10.1016/S1470-2045(15)00040-6. (PMID: 26254683)
    CrossrefPubMedGoogle Scholar
  • 14 Reynolds JV, Preston SR, O’Neill B. et al. Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. JCO 2023; 41 (Suppl. 04) 295-295 DOI: 10.1200/JCO.2023.41.4_suppl.295.
    CrossrefPubMedGoogle Scholar
  • 15 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine 2021; 384 (13) 1191-1203 DOI: 10.1056/NEJMoa2032125. (PMID: 33789008)
    CrossrefPubMedGoogle Scholar
  • 16 Morad G, Helmink BA, Sharma P. et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021; 184 (21) 5309-5337 DOI: 10.1016/j.cell.2021.09.020. (PMID: 34624224)
    CrossrefPubMedGoogle Scholar
  • 17 Janjigian YY, Shitara K, Moehler M etl al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 2021; 398: 27-40 DOI: 10.1016/S0140-6736(21)00797-2. (PMID: 34102137)
    CrossrefPubMedGoogle Scholar
  • 18 Sun JM, Shen L, Shah MA. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771 DOI: 10.1016/S0140-6736(21)01234-4. (PMID: 34454674)
    CrossrefPubMedGoogle Scholar
  • 19 Al-Batran SE, Lorenzen S, Thuss-Patience PC. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. JCO 2022; 40 (Suppl. 16) 4003-4003 DOI: 10.1200/JCO.2022.40.16_suppl.4003.
    CrossrefPubMedGoogle Scholar
  • 20 Patel SP, Othus M, Chen Y. et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine 2023; 388 (09) 813-823 DOI: 10.1056/NEJMoa2211437. (PMID: 36856617)
    CrossrefPubMedGoogle Scholar
  • 21 Bang Y, Chung H, Xu J. et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. JCO 2009; 27 (Suppl. 15) 4556-4556 DOI: 10.1200/jco.2009.27.15_suppl.4556.
    CrossrefPubMedGoogle Scholar
  • 22 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
    CrossrefPubMedGoogle Scholar
  • 23 Shitara K, Bang YJ, Iwasa S. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine 2020; 382 (25) 2419-2430 DOI: 10.1056/NEJMoa2004413. (PMID: 32469182)
    CrossrefPubMedGoogle Scholar
  • 24 Hofheinz RD, Hegewisch-Becker S, Kunzmann V. et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. International Journal of Cancer 2021; 149 (06) 1322-1331 DOI: 10.1002/ijc.33696.
    CrossrefPubMedGoogle Scholar
  • 25 Hofheinz RD, Haag GM, Ettrich TJ. et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO. JCO 2020; 38 (Suppl. 15) 4502-4502 DOI: 10.1200/JCO.2020.38.15_suppl.4502.
    CrossrefPubMedGoogle Scholar
  • 26 Wagner AD, Grabsch HI, Mauer M. et al. EORTC-1203-GITCG – the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 2019; 19 (01) 494 DOI: 10.1186/s12885-019-5675-4. (PMID: 31126258)
    CrossrefPubMedGoogle Scholar
  • 27 Stein A, Paschold L, Tintelnot J. et al. LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217). Annals of Oncology 2021; 32: S1331 DOI: 10.1001/jamaoncol.2022.2228. (PMID: 35737383)
    CrossrefPubMedGoogle Scholar
  • 28 Janjigian YY, Maron SB, Chatila WK. et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol 2020; 21 (06) 821-831 DOI: 10.1016/S1470-2045(20)30169-8. (PMID: 32437664)
    CrossrefPubMedGoogle Scholar
  • 29 Rha SY, Lee C kun, Kim HS. et al. A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update. JCO 2021; 39 (Suppl. 03) 218-218 DOI: 10.1200/JCO.2021.39.3_suppl.218.
    CrossrefPubMedGoogle Scholar
  • 30 An JY, Kim H, Cheong JH. et al. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131 (02) 505-511 DOI: 10.1002/ijc.26399. (PMID: 21898388)
    CrossrefPubMedGoogle Scholar
  • 31 André T, Tougeron D, Piessen G. et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol 2023; 41 (02) 255-265 DOI: 10.1200/JCO.22.00686. (PMID: 35969830)
    CrossrefPubMedGoogle Scholar
  • 32 Chalabi M, Verschoor YL, Berg J van den. et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Annals of Oncology 2022; 33: S1389
    CrossrefPubMedGoogle Scholar
  • 33 Pietrantonio F, Raimondi A, Lonardi S. et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). JCO 2023; 41 (Suppl. 04) 358-358 DOI: 10.1200/JCO.2023.41.4_suppl.358.
    CrossrefPubMedGoogle Scholar